Many oncolytic viruses are currently being tested as potential cancer therapeutic agents. To be effective, these viruses must replicate and propagate efficiently through the tumor mass. However, it is possible that the hypoxia that characterizes many tumors may be an obstacle to viral therapy because of its inhibition of viral replication and propagation. We, therefore, decided to test how oncolytic reovirus and its target cells respond to hypoxia. We found that reovirus infection suppresses hypoxia inducible factor (HIF)-1a protein levels (but not transcript abundance) in colon cancer HCT116 cells under CoCl 2 or hypoxia. Reovirus infection was able to reduce HIF-1a levels in both von Hippel Lindau (VHL)À/À renal carcinoma A498 and p53À/À HCT116 cells, indicating that the decrease of HIF-1a mediated by reovirus requires neither VHL nor p53 proteins. However, treatment with the inhibitor MG132 restored HIF-1a levels, suggesting that reovirus-induced HIF-1a decrease needs proteosomal activity. A498 VHLÀ/À cells with constitutive expression of HIF-1a were relatively resistant to reovirus-induced apoptosis when compared with A498 VHL þ / þ cells. However, we found that the use of YC-1 to target HIF-1a promoted reovirus-induced apoptosis in A498 VHLÀ/À cells. Accordingly, we propose that reovirus may be used together with YC-1 as a potential therapeutic agent against chemoresistant or radioresistant tumors that are hypoxic and show increased levels of HIF-1a.
Introduction
Hypoxia is a prevalent feature of solid tumors. Normal tissues have an oxygen partial pressure of 50-60 mm Hg, whereas most solid tumors have 10 mm Hg or less.
1,2 The hypoxic environment induces adaptive changes in tumor cell metabolism, which may distort the local microenvironment. These changes are clinically important, as hypoxia enhances a resistance to chemotherapy and radiation therapy 1 and is predictive of metastasis and malignancy. 1 Members of the hypoxia inducible factor (HIF) family transcription factors are crucial regulators of adaptive cellular responses to hypoxia. Over-expression of HIF-1a is a hallmark of diverse tumors, and its constitutive activation is frequently observed in aggressive tumor phenotypes. 3 HIF-1a is degraded via a proteosomedependent pathway mediated by ubiquitination under normoxic condition. 4 The oxygen-dependent turnover of HIF-1a is regulated by prolyl HIF hydroxylase (PHD) enzymes that hydroxylate two conserved proline residues located in the oxygen-dependent degradation domain of HIF-1a. During normoxia, hydroxylation of HIF-1a by PHDs allows its binding to von Hippel Lindau (VHL) protein, a recognition component of the E3 ubiquitin ligase complex. This interaction promotes the ubiquitination of HIF-1a, which is mediated by a complex that includes VHL, elongin-B, elongin-C, Cullin 2, and Rbx1, and subsequently leads to the degradation of HIF-1a. 5, 6 The human reovirus is a ubiquitous, non-enveloped virus with 10 segments of double-stranded RNA. 7, 8 Viral infection is usually restricted to the upper respiratory and gastrointestinal tracts but is often asymptomatic. [8] [9] [10] There is a strong body of evidence that Ras-transformed cells are preferentially susceptible to reovirus (type 3 Dearing strain) via inactivation of PKR (dsRNA-activated protein kinase) phosphorylation. 11, 12 Activation of the oncogenic Ras-signaling pathway enhances reoviral oncolysis in various types of human cancers, 11, 12 although our recent study shows that other signaling pathways may also contribute to the susceptibility of hepatic cancer cells to reoviral replication and oncolysis. 13 Reoviral efficacy has been examined in the treatment of gliomas in immunocompetent hosts and has not produced significant toxicities.
14 These results have led to the current tests of reovirus in several clinical trials. [15] [16] [17] Other groups have reported that reoviral oncolysis is associated with induction of apoptosis in various cancer types, 18 using signaling molecules such as TNF-related apoptosis-inducing ligand (TRAIL), 19 caspase 8 and JNK MAPK. 20 YC-1, 3-(5 0 -hydroxymethy-2 0 -furyl)-1-benzylindazole, was originally identified as a potential therapeutic drug for circulatory disorders, as it is able to inhibit platelet aggregation and vascular contraction by activating soluble guanylyl cyclase. 21 Recent studies have shown that YC-1 can also block HIF-1a activity, 22 apparently by inhibiting HIF-1a expression at a post-transcriptional level. 23 In addition, YC-1 suppresses tumor formation in vivo without apparent toxicity by inhibiting blood vessel formation. 23 Thus, YC-1 is regarded as a good lead compound for the development of HIF-1a-targeting anticancer agents. 24 In this study, we first show that reovirus targets HIF1a, leading to its degradation independently of VHL and p53. Furthermore, the concurrent use of YC-1 to target HIF-1a, accelerates the reovirus-induced apoptosis of renal carcinoma cells that constitutively express HIF-1a, providing a potentially attractive regimen for treatment of solid tumors under hypoxia.
Materials and methods

Cell culture and virus amplification
Murine L929, colon cancer HCT116 p53 þ / þ , and p53À/À cells (obtained from Dr B Vogelstein; The Johns Hopkins University), renal carcinoma A498 VHL þ / þ , and VHLÀ/À cells, and lung cancer A594 cells were cultured in DMEM supplemented with 10% FBS and 1% penicillin and streptomycin. The Dearing strain of reovirus serotype 3 was purchased from the ATCC (Manassas, VA) and was propagated in L929 cells. The virus was purified as described elsewhere 8, 25 and viral titer was determined as plaque forming unit.
Reagents and antibodies
Cycloheximide and YC-1 were purchased from Sigma (St Louis, MO) and MG132 was obtained from Calbochem (San Diego, CA). For immunoblotting, anti-b-tubulin and HRP-conjugated secondary antibodies were purchased from Santa Cruz Biotech (Santa Cruz, CA) and anti-HIF-1a antibody was obtained from BD Biosciences (San Jose, CA). Anti-caspase 8 was purchased from Cell Signaling (Danvers, MA). Anti-reovirus antibodies described earlier 7 were used for the detection of reoviral proteins such as l, m, and s.
Western blotting assay
Cells were harvested and lysed with lysis buffer (150 mM NaCl, 1% NP-40, 50 mM Tris-HCl [pH 7.5]) containing 0.1 mM Na 2 VO 3 , 1mM NaF and protease inhibitors (Sigma). For immunoblotting, proteins from whole-cell lysates were resolved by 10 or 12% SDS-PAGE and then transferred to nitrocellulose membranes. Primary antibodies were used at 1:1000 or 1:2000 dilutions, and secondary antibodies conjugated with horseradish peroxidase were used at 1:2000 dilutions in 5% non-fat dry milk. After final washing, nitrocellulose membranes were exposed for an enhanced chemiluminescence assay using LAS 3000 (Fuji, Japan).
RT-PCR analysis
Total RNA was extracted from the cells by Trizol reagent (Invitrogen, Carlsbad, CA) in accordance with the manufacturer's instructions. Three micrograms of the total RNA was converted to cDNA using Superscript II reverse transcriptase (Invitrogen), and PCR was performed using specific primers described elsewhere. 26 The cDNAs of each sample were diluted, and PCR was run at the optimized cycle number. b-actin mRNA was measured as an internal standard. After amplification, the products were subjected to electrophoresis on 1.5% agarose and detected by ethidium bromide staining.
Results
Reovirus infection induces the rapid degradation of HIF-1a
As many solid tumors display features of hypoxia, 1,2 we wondered how reovirus might respond to tumor cells growing under hypoxic conditions. To test this, we grew HCT116 colon cancer cells under CoCl 2 (which mimics a hypoxic condition), infected them with reovirus, and measured the protein level of HIF-1a at 12 h postinfection. We found that reovirus infection significantly reduced levels of HIF-1a protein that had first been enhanced by CoCl 2 ( Figure 1a) . A similar effect was observed in lung epithelial A549 cells ( Figure 1a) . Furthermore, when HCT116 cells under hypoxia (2% O 2 ) were treated with reovirus, HIF-1a levels were again drastically decreased at 12 h post-infection ( Figure 1b) . Thus, reovirus infection significantly reduces the abundance of HIF-1a protein that is otherwise enhanced by hypoxia. To test whether the reovirus-induced decrease in HIF-1a abundance occurs at the transcriptional level, we analyzed mRNA levels of HIF-1a and Glut-1 (one of HF-1a target genes) from cells infected with reovirus during hypoxia. We identified no significant alteration in the abundance of HIF-1a transcript after hypoxia/CoCl 2 (even though HIF-1a protein levels changed dramatically; Figures 1a and b) or reovirus treatment, but saw a partially reduced level of Glut-1 transcripts when the cells were treated with reovirus ( Figure 1c ). The decreased level of Glut-1 transcript may be attributed to the decrease of HIF-1a protein levels during reovirus infection in CoCl 2 -treated or hypoxic HCT116 cells. These results suggest that reovirus induces the rapid decrease of HIF-1a protein abundance at a post-transcriptional level.
Reovirus-induced HIF-1a decrease is independent of VHL and p53 but requires proteosomes It has previously been shown that HIF-1a protein is degraded via its binding to VHL protein, which functions as a recognition component of the E3 ubiquitin ligase complex under normoxia. 5, 6 We, therefore, wondered whether VHL protein might be involved in the reovirusinduced decrease in HIF-1a abundance. We thus used renal carcinoma A498 VHLÀ/À cells and the same cells reconstituted with wild-type VHL (VHL þ / þ ). As shown in Figure 2a , the absence of VHL conferred stable expression of HIF-1a even under normoxic conditions in A498 VHLÀ/À cells. However, the restoration of VHL induced the rapid degradation of HIF-1a to undetectable levels under normoxia, as expected. When A498 VHLÀ/À cells were treated with reovirus, HIF-1a gradually decreased in abundance especially by 24 h post-infection (Figure 2a ). This result indicates that reovirus-induced HIF-1a degradation can proceed independently of VHL E3 ubiquitin ligase activity.
Next, as p53 protein as a tumor suppressor has an important function in cell cycle regulation and apoptosis and is also known to be regulated in part by VHL through the suppression of Mdm2-mediated ubiquitination, [27] [28] [29] we wondered whether p53 might be involved in reovirusinduced HIF-1a degradation. To answer this question, we used HCT116 cells p53 þ / þ and p53À/À cells. When HCT116 p53 þ / þ and p53À/À cells were treated with CoCl 2 and reovirus, and HIF-1a protein level was analyzed by immunoblotting, we found that HIF-1a protein levels were diminished by reovirus infection irrespective of p53 status (Figure 2b ). Taken together, we conclude that HIF-1a degradation mediated by reovirus infection is independent of VHL and p53.
Next, we wondered how reovirus infection could induce the degradation of HIF-1a protein without the involvement of VHL. To answer this question, HCT 116 cells under CoCl 2 were treated with reovirus alone or reovirus and MG132, a proteosome inhibitor. We found that MG132 completely blocked reovirus-induced HIF-1a degradation, leading to HIF-1a levels that were actually greater than those of HCT116 treated with CoCl 2 alone (Figure 2c) . Next, we examined whether HIF-1a degradation mediated by reovirus still occurs via the proteosome . The cells were harvested after 12 h under hypoxia and the expression of HIF-1a was examined by immunoblotting using anti-HIF-1a antibody. (c) HCT116 cells were treated with CoCl 2 (100 mM) or cultured under hypoxia and followed by reovirus exposure (MOI ¼ 10). The cells were harvested at 12 h post-infection and total RNA was isolated followed by reverse transcription. HIF-1a and Glut-1 sequences were amplified with their specific primers and visualized on 1.5% agarose gel after ethidium bromide staining. b-actin was used for an internal control.
in cells without VHL. MG132 treatment again restored the reduced HIF-1a level due to reovirus infection to a greater degree than untreated A498 VHLÀ/À cells (Figure 2c ). These results suggest that HIF-1a degradation caused by reovirus infection occurs via proteosomes irrespective of VHL status.
We also wondered whether reovirus-induced HIF-1a degradation requires a protein synthesis in the infected cells. To test this, HCT116 under CoCl 2 and A498 VHLÀ/À cells were infected with reovirus in the presence of cycloheximide. As shown in Figure 2d , the inhibition of protein synthesis with cycloheximide further enhanced HIF-1a degradation that was induced by reovirus in HCT116 under CoCl 2 and in A498 VHLÀ/À cells. This result implies that HIF-1a degradation induced by reovirus does not require protein synthesis at least, although the mechanism of cycloheximide-induced acceleration of reovirus-induced HIF-1a degradation remains unclear.
Constitutive expression of HIF-1a limits reovirus-induced apoptosis
To explore the biological consequence of a constitutive expression of HIF-1a in cells exposed to reovirus infection, we evaluated reovirus-mediated cell cytotoxicity in A498 VHL þ / þ or À/À cells. Of interest, we found that A498 VHL þ / þ cells are more sensitive to reovirusinduced cell death compared with A498 VHLÀ/À cells (Figure 3a) . When live cells in the two cell lines were counted at 96 h post-infection using Trypan blue exclusion, A498 VHLÀ/À cells exhibited approximately twofold more live cells than A498 VHL þ / þ cells ( Figure 3b) . Next, we wondered what might cause the greater sensitivity of A498 VHL þ / þ cells to cell death during reovirus infection. To answer this question, we examined reoviral protein levels in whole-cell lysates from reovirus-infected A498 VHL þ / þ and VHLÀ/À cells. We found that A498 VHL þ / þ cells show slightly higher levels of reovirus proteins compared with A498 VHLÀ/À cells (Figure 3c ). The result suggests that greater viral replication might be associated with the sensitization of A498 VHL þ / þ cells to cell death. Consistent with this result, we found that A498 VHL þ / þ cells exhibited slightly higher levels of the TRAIL death receptor (DR)4 expression, a TRAIL receptor (data not shown) and more active caspase 8 than did A498 VHLÀ/À cells (Figure 3d ). Taken together, we suggest that the constitutive expression of HIF-1a in VHLÀ/À cells limits reoviral multiplication and leads to the inhibition of cellular apoptosis to some extent, although we cannot presently rule out the possibility that the absence of VHL protein may also modulate apoptotic responses through other pathways as well.
Introduction of YC-1, a drug-targeting HIF-1a promotes reovirus-induced apoptosis in A498 VHLÀ/À cells As the constitutive expression of HIF-1a seems to restrict reoviral replication and subsequent cell death (Figure 3) , we attempted to overcome this hurdle using YC-1, a compound-targeting HIF-1a. First, we identified a minimal concentration of YC-1 necessary to achieve the degradation of HIF-1a so that we could avoid toxicity of YC-1 on A498 VHLÀ/À cells. Although we found that 0.5 and 1 mM YC-1 efficiently reduced HIF-1a levels (Figure 4a ), these concentrations also induced apoptosis in B40 and 70% of the cells at 12 h post-treatment, respectively (data not shown). We therefore used 0.1 mM YC-1 during combined treatment with reovirus and confirmed the dramatic degradation of HIF-1a under the co-administration compared with the treatment with reovirus or YC-1 alone (Figure 4b ). We then examined whether the co-administration efficiently kills renal carcinoma A498 VHLÀ/À cells compared to treatment with reovirus or YC-1 alone. As shown in Figure 4c , YC-1 treatment alone started to induce cell death after 12 h of exposure at 0.1 mM and the viable cell number decreased to B50% of the cells at 24 h and 25% by 48 h posttreatment. Renal carcinoma A498 VHLÀ/À cells were relatively resistant to reovirus infection, and we could not detect significant cell death until 48 h post-infection. However, we could see reovirus-induced cell death at 72 and 96 h post-infection (data not shown, Figure 3a) . Furthermore, combined treatment with YC-1 and reovirus induced the most rapid kinetic of cell death, leaving about 10% of the uninfected cells at 48 h post-treatment, compared with treatment of YC-1 or reovirus alone (Figure 4c ). The result thus indicates that co-administration of YC-1 and reovirus may provide an efficient cancer therapeutic strategy for the treatment of solid tumors by overcoming the inhibitory effects of HIF-1a.
Discussion
HIF-1a can be activated not only by hypoxia but also by a number of stimulants including cytokines, LPS, and certain bacterial infections. 30 In addition, HIF-1a is upregulated on infection with hepatitis B virus through interaction with hepatitis B virus X protein. 31 LMP-1, a primary oncoprotein of Epstein-Barr virus, has also been reported to induce synthesis of HIF-1a. 32 In contrast to the data showing that some viruses can activate HIF-1a, we show here that this protein, which is often elevated in malignant tumors under hypoxic or stressed conditions, is actually degraded following reovirus infection with downregulation achieved at the post-transcriptional level. We found that down-regulation of HIF-1a is independent of oxygen and VHL and p53 proteins. A recent study showed that HIF-1a protein can be sumorylated, thereby recruiting VHL, and leading to the down-regulation of HIF-1a. 33 However, sumo-mediated HIF-1a down-regulation still requires VHL and thus this pathway is likely independent of the mechanism that we observe for reovirus-mediated HIF-1a degradation. Another study has reported that the receptor of activated protein kinase C (Rack-1) is able to trigger the degradation of HIF-1a in a manner that is independent of oxygen, PHD, and VHL. 34 Rack-1 competes with heat shock protein (HSP)90 for binding to HIF-1a through PAS A domain. 34 Binding of Rack-1 to HIF-1a recruits elongin-c, promoting ubiquitination of HIF-1a. 34 Thus, it is possible that reovirus may have a function as a modulator of Rack-1 or HSP90 activity, leading to HIF-1a degradation. The underlying mechanism of reovirus-mediated HIF-1a degradation remains under investigation.
Many lines of evidence have shown that the constitutive expression of HIF-1a functions as a hurdle for the treatment of chemotherapy-or radiotherapy-resistant cancer cells. Reovirus infection induces the degradation of HIF-1a, but the constitutive expression of HIF-1a restricts reovirus replication to some extents. Other studies have also shown that the renal carcinoma 786-O cell line with constitutive expression of HIF-1a inhibits the replication of vesicular stomatitis virus due to the upregulation of immune/defense response such as, IFN-b, OAS, and interferon stimulated genes. 35 When we, therefore, examined IFN-b and OAS transcripts in our study, we surprisingly found no significant difference in the levels of IFN-b or OAS transcripts between A498 VHL þ / þ and A498 VHLÀ/À cells (data not shown). This might be attributed to the different backgrounds of cell line and viruses. On the other hand, based on several lines of evidence including that (1) loss of HIF-1a reduces non-hypoxia-mediated cell proliferation in vitro and in vivo, 36 and (2) over-expression of HIF-1a is associated with the proliferation and invasiveness of a gastric cancer cells, 37 this may explain at least in part the relative resistance of A498 VHLÀ/À cells to reovirus-mediated apoptosis.
Therefore, strategies to target HIF-1a such as screening small molecules from chemical libraries have been developed in an effort to improve the treatment of solid tumors. Several small molecule inhibitors of HIF-1a activity have in fact been shown to harbor anti-tumor and anti-angiogenic activity in addition to other known roles. These include the microtubule depolarizing agent 2-methoxyestiradiol; 38 inhibitors of the redox protein thioredoxin-1; 39 YC-1, an agent developed for circulatory disorder; 23 and the HSP90 inhibitor, geldanamycin. Herein, we have described the potential utility of YC-1. Some lines of evidence have shown that the introduction of Mdm2, a binding partner of HIF-1a, reverses YC-1-mediated HIF-1a down-regulation, suggesting the involvement of Mdm2 in the regulation of HIF-1a, with an effect that is opposite to that of YC-1. 40 Recent studies have also reported that the Akt/NF-kB signaling pathway contributes to YC-1-mediated HIF-1a down-regulation. 40 Although earlier studies reported a low toxicity of YC-1 on other cell lines, we used an even lower concentration due to some cytotoxicity of YC-1 on A498 VHLÀ/À cells. 21, 23 Although the concentration we used is not enough to completely eliminate HIF-1a expression, combined treatment with YC-1 and reovirus nevertheless partially reduced the expression of HIF-1a and promoted reovirus-induced cell death. We suggest that the combined treatment with these two agents may prove to be a novel strategy to treat solid tumors constitutively expressing HIF-1a.
